February 7, 2018
The Company is an FDA-registered Drug cGMP Labeler and Distributor operating across the U.S. The Company sells a select portfolio of, frequently prescribed medications to a proprietary network of independent pharmacies and distributors. The Company distributes directly to customers allowing participating pharmacies and distributors to realize higher margins when dispensing the products to patients. The business model also yields strong margins for the Company as well.
The Company has three exclusive agreements with drug manufacturers, and two additional exclusives are scheduled to launch during Q1 2018.
Sales have quadrupled since the Company’s inception just three years ago and achieved a 95% gross margin in 2017 with $13.8 million in adjusted EBITDA. Management expects sales to increase 62% and reach over $34.9 million in 2018 with more than $18.9 million in adjusted EBITDA.
Seeing an unmet need in the market, the Company developed a proprietary methodology of bringing commonly used products to market in a way that produces attractive margins for independent pharmacies. This is a high-margin, fast-growing business that is easy to scale and relocate. There is significant upside still ahead.
Management believes that the Company has created barriers to entry to help sustain market position and thwart competitive pressures. The Company’s proprietary method of product selection, exclusive distribution licenses and effective marketing strategies make it a unique growth platform within the biomedical supply chain. Management believes that it will continue to bring on two new products every 12 rolling months, at a minimum.